Schwartz S, Cohen M M, Panny S R, Beisel J H, Vora S
Am J Hum Genet. 1984 Jul;36(4):750-9.
A proband, clinically thought to have trisomy 10p, was found to have an inverted duplication of 10p [46, XY, inv dup(10)(qter----p15.3::p15.3----p 11.1:)]. The phenotypic findings and cytogenetic observations were supported by relevant biochemical studies. The activity of phosphofructokinase (platelet-type; PFKP), previously localized to 10p, and hexokinase-I (HKI), putatively on 10p, demonstrated 153% and 149% of control activity in the proband's fibroblasts. These gene-dosage effects confirmed the clinical and cytogenetic observations as well as the localization of HKI to 10p. Additionally, phosphofructokinase (PFK) and hexokinase (HK), which are control points in the glycolytic pathway, were shown to be syntenic.
一名临床诊断为10号染色体短臂三体的先证者,被发现存在10号染色体短臂的反向重复[46, XY, inv dup(10)(qter----p15.3::p15.3----p 11.1:)]。相关生化研究支持了表型发现和细胞遗传学观察结果。先前定位于10号染色体短臂的磷酸果糖激酶(血小板型;PFKP)以及推测位于10号染色体短臂的己糖激酶-I(HKI)的活性,在先证者的成纤维细胞中分别显示为对照活性的153%和149%。这些基因剂量效应证实了临床和细胞遗传学观察结果以及HKI定位于10号染色体短臂。此外,糖酵解途径中的控制点磷酸果糖激酶(PFK)和己糖激酶(HK)显示为同线。